ABBV
AbbVie Inc.
—
216.63 $
-4.6000 (%-2.08)
Previous Close: 221.23
Day Low₺215.37
Day High₺222.35
ABBV: AbbVie Inc. Financials
ABBV Income Statement
Total revenue
Net income
Gross margin TTM
70.24%
Operating margin TTM
32.85%
Net profit margin TTM
6.91%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 61,160,000,000 | 56,334,000,000 | 54,318,000,000 | 58,054,000,000 |
| Operating income | 20,091,000,000 | 9,137,000,000 | 12,757,000,000 | 18,117,000,000 |
| Net income | 4,226,000,000 | 4,278,000,000 | 4,863,000,000 | 11,836,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 61,160,000,000 | 56,334,000,000 | 54,318,000,000 | 58,054,000,000 |
| Cost of revenue | 18,204,000,000 | 16,904,000,000 | 20,415,000,000 | 17,414,000,000 |
| Gross profit | 42,956,000,000 | 39,430,000,000 | 33,903,000,000 | 40,640,000,000 |
| Research and development expenses | 9,096,000,000 | 12,791,000,000 | 7,675,000,000 | 6,510,000,000 |
| General and administrative expenses | 0 | 0 | 0 | 0 |
| Selling and marketing expenses | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenses | 14,010,000,000 | 14,752,000,000 | 12,872,000,000 | 15,260,000,000 |
| Other expenses | -241,000,000 | 2,750,000,000 | 599,000,000 | 753,000,000 |
| Operating expenses | 22,865,000,000 | 30,293,000,000 | 21,146,000,000 | 22,523,000,000 |
| Cost and expenses | 41,069,000,000 | 47,197,000,000 | 41,561,000,000 | 39,937,000,000 |
| Net interest income | -2,627,000,000 | -2,160,000,000 | -1,684,000,000 | -2,044,000,000 |
| Interest income | 266,000,000 | 648,000,000 | 540,000,000 | 186,000,000 |
| Interest expense | 2,893,000,000 | 2,808,000,000 | 2,224,000,000 | 2,230,000,000 |
| Depreciation and amortization | 8,139,000,000 | 8,386,000,000 | 8,698,000,000 | 8,467,000,000 |
| EBITDA | 17,629,000,000 | 14,910,000,000 | 17,172,000,000 | 24,174,000,000 |
| EBIT | 9,490,000,000 | 6,524,000,000 | 8,474,000,000 | 15,707,000,000 |
| Non-operating income (excl. interest) | 10,601,000,000 | 2,613,000,000 | 4,283,000,000 | 2,410,000,000 |
| Operating income | 20,091,000,000 | 9,137,000,000 | 12,757,000,000 | 18,117,000,000 |
| Total other income/expenses (net) | -13,494,000,000 | -5,421,000,000 | -6,507,000,000 | -4,640,000,000 |
| Income before tax | 6,597,000,000 | 3,716,000,000 | 6,250,000,000 | 13,477,000,000 |
| Income tax expense | 2,364,000,000 | -570,000,000 | 1,377,000,000 | 1,632,000,000 |
| Net income from continuing operations | 4,233,000,000 | 4,286,000,000 | 4,873,000,000 | 11,845,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 4,226,000,000 | 4,278,000,000 | 4,863,000,000 | 11,836,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 4,196,000,000 | 4,238,000,000 | 4,820,000,000 | 11,782,000,000 |
| EPS | 2 | 2 | 3 | 7 |
| Diluted EPS | 2 | 2 | 3 | 7 |
| Weighted average shares outstanding | 1,780,392,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 |
| Weighted average diluted shares outstanding | 1,774,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 |